Food and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibody therapy bamlanivimab/etesevimab for use in COVID-19…
The Food and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibody therapy bamlanivimab/etesevimab for use in COVID-19 positive adults and children aged 12 and older who are at high risk of severe disease.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthFood and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibody therapy bamlanivimab/etesevimab for use in COVID-19…
View Premium plansBrowse free archive reportsThe Food and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibody therapy bamlanivimab/etesevimab for use in COVID-19 positive adults and children aged 12 and older who are at high risk of severe disease.